Crestor boost for AstraZeneca
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Anglo-Swedish drug group AstraZeneca got a boost yesterday when its anti-cholesterol treatment, Crestor, was shown to cut the chances of heart attacks and strokes dramatically among patients with healthy cholesterol levels.
The UK's second biggest drugs maker said that the results of its own two year Jupiter study has shown that the risk of heart attacks among those without high cholesterol levels, but who are still susceptible to cardiac arrests, was cut by 54 per cent. The threat of strokes among the same group of people fell by 48 per cent.
The group's share price closed up 3.2 per cent at 2,770p, with analysts arguing that sales of Crestor could be pushed well above the $2.8bn achieved last year.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments